Stock Movers Novo Nordisk Slips, Fresenius & Telefónica Earnings
Feb 24, 2026
Chloe Malay, a Bloomberg reporter who analyzes company results, breaks down reactions to Novo Nordisk’s CagriSema trial miss. She covers Fresenius Medical Care’s muted outlook and why markets pulled back. She also explains Telefónica’s Q4 resilience, with Spain and Brazil offsetting weakness elsewhere.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk's CagriSema Readout Hands Lead To Eli Lilly
- Novo Nordisk's next-generation obesity shot CagriSema produced disappointing trial data that ceded leadership to Eli Lilly.
- Analysts called the readout a "worst case scenario," triggering downgrades and extending a share slump after earlier weak 2026 guidance.
Analyst Cuts Compound Novo Nordisk's Stock Pressure
- Analysts cut Novo Nordisk ratings and price targets after the trial, including JP Morgan and Nordea downgrades.
- The selloff compounds earlier stock falls following disappointing earnings and a weak 2026 outlook, leaving the company needing a new catalyst.
Fresenius Outlook Signals Profit Plateau
- Fresenius Medical Care warned of broadly flat earnings for 2026 after a surge in profit last year.
- Management's gains were driven by pricing and efficiency rather than patient growth, raising sustainability concerns and disappointing investors.